Le Lézard

Pfizer's BRAFTOVI® Regimen with Additional Chemotherapy Backbone Increased Response Rates for Certain Patients with Metastatic Colorectal Cancer

Pfizer Inc. today announced positive results from Cohort 3, a separate randomized cohort of the pivotal BREAKWATER trial, ...
The Malaysian Reserve

RYBREVANT® (amivantamab-vmjw) longer-term results show promising and durable responses in difficult-to-treat colorectal cancer

Over 70 percent of patients in the first-line subgroup responded to amivantamab plus chemotherapy with most responses lasting beyond 16 monthsNotable ...
Targeted Oncology

Patient Case #1: Newly Diagnosed Stage 3A NSCLC

A 62-year-old woman with stage IIIA lung cancer faces complex diagnostic and treatment decisions, highlighting the importance ...
pharmaphorum

Now Iktos teams up with Pierre Fabre in oncology

In the same week that Servier announced its partnership with Paris, France-based Iktos, now Pierre Fabre Laboratories has ...

Pierre Fabre Laboratories and Iktos Announce an Integrated AI-Driven Drug Discovery Collaboration in Oncology

Pierre Fabre Laboratories and Iktos, a global leader in Artificial Intelligence (AI) and Robotics on drug discovery, today ...
BMJ Case Reports

Unusually aggressive malignant glomus tumour of cutaneous origin

Glomus tumours are uncommon, typically benign neoplasms of specialised dermal thermoregulatory structures known as glomus ...
Healio

‘Reassuring’ data show most with NSCLC receive guideline-concordant biomarker testing

Biomarker testing has become “increasingly critical” in the care of non-small cell lung cancer.A new investigation into testing rates proved “reassuring” to Kenneth L. Kehl, MD, MPH, assistant ...

Liquid biopsy advances could yield new tool for detecting lung cancer mutations

In Brazil, the early detection of genetic alterations in lung cancer through liquid biopsies could be a valuable tool for ...